Ambulatory Parkinson's Disease Dyskinesia Monitor for Drug Therapy Titration

Kinesia-D Phase II In-Clinic Continuous Assessment Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02125825

Acronym

Kinesia-D

Enrollment

Registered

2014-04-29

Start date

2014-07-31

Completion date

2014-12-31

Last updated

2016-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease

Brief summary

The objective is to assess a compact, portable, wireless movement disorder system with continuous monitoring capabilities to detect and quantify the severity of levodopa-induced dyskinesia in Parkinson's disease.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

21 Years to No maximum

Healthy volunteers

Inclusion criteria

* Diagnosis of idiopathic Parkinson's disease * Clinical history of levodopa-induced dyskinesia * 21 Years of age or older * Stage 2 - 4 OFF-medication on the Hoehn and Yahr scale

Exclusion criteria

* Dementia (determined by a neuropsychological assessment) * Severe tremor unaffected by levodopa

Design outcomes

Primary

Measure	Time frame	Description
Correlation between motion sensor features and clinician-rated dyskinesia severity	All data will be collected within a single session not to exceed 3 hours	Motor function (movement speed and magnitude measured with a motion sensor) will be collected for a period of 2 hours after taking normally prescribed dose of levodopa.

Countries

United States

Outcome results